類肉瘤病：新型療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 預計到 2035 年，法國類肉瘤病市場將從約 2,200 萬美元成長到 5,500 萬美元，這表明市場將大幅擴張。
• 以下因素正在推動市場成長：
• 在慢性疾病的治療中，免疫抑制療法和生物製藥的使用日益增加。
• 診斷方法的改進和多器官疾病長期監測的進步
• 市場規模的擴大是由治療週期延長和疑難雜症先進療法的日益普及所推動的。
• 未來的成長取決於標靶免疫調節療法的發展以及慢性進行性類肉瘤病管理策略的改進。

對類肉瘤病和TPP新興療法的見解

Thelansis 的「結節類肉瘤病新興療法、未滿足的需求和目標產品概況 (TPP) 洞察報告 - 2026」對該適應症的關鍵新興療法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計和關鍵意見領袖 (KOL) 的見解。

類肉瘤病概述

類肉瘤病是一種多器官肉芽腫性疾病，其病因尚未完全明確。它是由遺傳易感個體對未知抗原觸發的先天性和適應性免疫反應失調所致，其特徵是受累器官中出現由活化巨噬細胞、上皮樣細胞和CD4+ T淋巴細胞組成的非乾酪性肉芽腫的病理性積聚。超過90%的病例病變位於肺部和胸內淋巴結，常涉及皮膚、眼、肝、脾、心臟和神經系統。患者的臨床表現多種多樣，從偶然發現的無症狀病例到急性、通常可自發性緩解的洛夫格倫症候群（Lofgren's syndrome），後者以雙側肺門淋巴結腫大、結節性紅斑和關節炎為特徵，並可能伴有慢性觀察、乾咳、乏力和器官特異性症狀。診斷是基於臨床、觀察和組織病理學觀察的綜合考量。乳房攝影篩檢顯示雙側肺門淋巴結腫大，血清血管緊張素轉換酶（ACE）和可溶性白細胞介素-2受體（sIL-2R）水平升高可作為輔助生物標記，非乾酪性肉芽腫需通過切片檢查證實，並排除感染疾病和惡性腫瘤等類似疾病。對於有症狀的病例和進行性疾病，糖皮質激素仍是治療的基礎，而胺基甲基葉酸和Azathioprine則可作為慢性疾病的糖皮質激素替代藥物。對於難治性病例，抗TNF生物製藥，包括羥氯喹和Infliximab，可能有效。由於存在危及生命的併發症風險，心臟類肉瘤病和類肉瘤病需要特別密切的後續觀察。預後因病例而異。許多病例可自發性緩解，但慢性進行性疾病需要長期的多學科後續觀察和以患者為中心的輔助治療。

主要亮點

• 在法國，預計到 2025 年，類肉瘤病病患者人數將約為 22,210 人，到 2035 年將約為 23,815 人，這反映出該疾病負擔的逐漸增加。
• 肺類肉瘤病仍然是主要的臨床表現，佔確診病例的大多數。
• 慢性進行性疾病和肺外病變仍是導致長期發生率的重要因素。
• 皮質類固醇仍然是標準治療方法，但由於類固醇的長期毒性，減少類固醇使用的免疫抑制療法的使用正在增加。
• 人們對生物目標療法的興趣日益濃厚，這為難治性和重症類肉瘤病病患者提供了更多治療選擇。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興療法條件的患者
• 大公司
• 主要作用機制
• 發布日期預測等。
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要療法的有效性
• 未滿足需求的關鍵領域
• 主要未滿足需求的市場規模估算
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵意見領袖對領先新興療法的見解
• 意識
• 預期用途/處理線
• 主要未滿足需求得到滿足的程度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要療法概述及關鍵意見領袖見解
• 新興療法
• 重點
• 診斷和治療過程/演算法
• 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興療法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興療法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Sarcoidosis Emerging Therapy and TPP Insights

Thelansis's "Sarcoidosis Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Sarcoidosis Overview

Sarcoidosis is a multisystem granulomatous disorder of incompletely understood aetiology, characterised by the pathological accumulation of non-caseating granulomas - composed of activated macrophages, epithelioid cells, and CD4+ T-lymphocytes - in affected organs, driven by dysregulated innate and adaptive immune responses to unidentified antigenic triggers in genetically susceptible individuals. The lungs and intrathoracic lymph nodes are involved in over 90% of cases, with frequent additional involvement of skin, eyes, liver, spleen, heart, and nervous system. Patients present heterogeneously - ranging from asymptomatic incidental discovery to Lofgren syndrome, an acute, typically self-limiting presentation of bilateral hilar lymphadenopathy, erythema nodosum, and arthritis - alongside chronic dyspnoea, dry cough, fatigue, and organ-specific manifestations. Diagnosis integrates clinical, radiological, and histopathological findings; chest imaging demonstrating bilateral hilar lymphadenopathy, elevated serum ACE and sIL-2R as supportive biomarkers, and biopsy confirming non-caseating granulomas while excluding infectious and malignant mimics. Corticosteroids remain the therapeutic cornerstone for symptomatic or progressive disease, with methotrexate and azathioprine as steroid-sparing agents for chronic disease. Refractory cases may benefit from hydroxychloroquine or anti-TNF biologics including infliximab. Cardiac and neurosarcoidosis demand particularly vigilant monitoring given life-threatening complication risk. Prognosis varies considerably; spontaneous remission occurs in many, while chronic progressive disease necessitates long-term multidisciplinary surveillance and patient-centred supportive management.

Key Highlights

• In France, sarcoidosis prevalence cases are projected to increase from approximately 22,210 in 2025 to nearly 23,815 by 2035, reflecting a gradual increase in disease burden.
• Pulmonary sarcoidosis remains the predominant clinical presentation, accounting for the majority of diagnosed cases.
• Chronic progressive disease and extrapulmonary involvement continue to contribute significantly to long-term morbidity.
• Corticosteroids remain the standard of care; however, long-term steroid toxicity drives increasing use of steroid-sparing immunosuppressive therapies.
• Growing interest in targeted biologic therapies is expanding treatment options for refractory and severe sarcoidosis cases.

Market Overview

• The France sarcoidosis market is projected to grow from approximately $22 MN to $55 MN by 2035, reflecting notable market expansion.
• Market growth is supported by:
• Increasing use of immunosuppressive and biologic therapies in chronic disease management
• Improved diagnosis and long-term monitoring of multisystem disease involvement
• Market value growth is driven by prolonged treatment duration and increasing adoption of advanced therapies in refractory disease.
• Future growth will depend on development of targeted immunomodulatory therapies and improved management strategies for chronic progressive sarcoidosis.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)